USPTO serial 79339791
OPTIMER
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 10, 2024
- Examiner
- O'BRIEN, JENNIFER LYNN
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with OPTIMER?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Charles J. Meyer
Charles J. Meyer Woodard, Emhardt, Henry, Reeves & Wagner111 Monument Circle, Suite 3700Indianapolis, IN 46204UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Reagents for medical use; chemical reagents for medical use; medical, veterinary, clinical, diagnostic and pharmaceutical reagents, agents, chemicals, materials, substances and preparations, namely, clinical medical reagents, reagents for medical use, veterinary diagnostic reagents, chemical reagents for medical purposes, diagnostic agents, preparations and substances for medical purposes; optimised aptamer molecules for medical and veterinary use, namely, veterinary diagnostic reagents, chemical reagents for medical purposes, diagnostic media for bacteriological cultures; medical and veterinary diagnostic reagents and assays for testing of body fluids; medical and veterinary diagnostic test strips for the analysis of blood, urine, saliva, human tissue and animal tissue; diagnostic biomarker reagents for medical and veterinary purposes; reagents and media for medical and veterinary diagnostic or treatment purposes, namely, diagnostic reagents and contrast media for medical use; nucleic acids for medical, veterinary, diagnostic and pharmaceutical purposes, namely, nucleic acids being diagnostic reagents and chemical reagents for medical and veterinary purposes; nucleic acid sequences for medical, veterinary, diagnostic and pharmaceutical purposes; diagnostic testing kits comprised of medical diagnostic reagents, assays, monoclonal antibodies, buffers and reagents for testing of bodily fluids, human tissue and animal tissue for use in disease detection; diagnostic reagents for medical and veterinary use for sale in kit form; diagnostic kits comprising specimen receptors and reagents for medical, veterinary and diagnostic testing in the nature of diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids, human tissue and animal tissue for use in disease detection; medical and veterinary diagnostic reagents and assays for testing of fluids | ACTIVE | — |
| 042 | Research and development services in the field of medical diagnostics and medical testing; product design and development of diagnostic apparatus, instruments, equipment, tools and devices; product research, design and development in the field of diagnostic preparations; product research, design and development of reagents; product research, design and development of aptamer reagents; product research, design and development of aptamer reagents for integration into diagnostic platforms; product research, design and development of reagents for therapeutic applications; product research, design and development of aptamer reagents for therapeutic applications; custom product development of reagents; custom product development of aptamer reagents; medical research, namely, optimsation of aptamer molecules; product research, design and development of nucleic acids for medical, veterinary, diagnostic and pharmaceutical purposes; product research, design and development of nucleic acid sequences for medical, veterinary, diagnostic and pharmaceutical purposes laboratory testing services, namely, testing of pharmaceuticals; medical and scientific laboratory services for analytical testing; design and development of testing and analysis methods, namely, research and development of advanced learning technologies and teaching methods; medical and scientific laboratory services, namely, preparation of biological samples for testing and analysis in research laboratories; medical and veterinary research services; medical and veterinary laboratory services; scientific research and investigations for medical and veterinary purposes; medical and scientific laboratory services, namely, analysis of human and animal tissues and samples for medical and veterinary research; biological research, clinical research, medical research and veterinary research in the field of medical diagnostics and medical testing; provision of information and data relating to medical and veterinary research and development; information and advisory services in respect of the aforementioned services | ACTIVE | — |
| 044 | Medical, veterinary and diagnostic services, namely, medical testing for diagnostic or treatment purposes, virus testing for medical diagnostic or treatment purposes, veterinary testing for diagnostic or treatment purposes; medical and veterinary testing services, namely, genetic testing for medical, diagnostic and treatment purposes, veterinary testing for diagnostic or treatment purposes; medical and veterinary testing for diagnostic or treatment purposes; medical and veterinary analysis services for diagnostic and treatment purposes, namely, medical analysis for the diagnosis and treatment of persons, medical analysis for the diagnosis and treatment of animals; medical and veterinary testing services relating to diagnosis and treatment; medical and veterinary analysis services, namely, medical analysis for the diagnosis and treatment of persons, medical analysis for the diagnosis and treatment of animals; information and advisory services in respect of the aforementioned services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Aptamer Group Limited
- Other trademarks owned by Aptamer Group Limited
- Other trademarks owned by Aptamer Group Limited
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named OPTIMER
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 19, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 24, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 8, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 8, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 10, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 10, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 10, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 10, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 10, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 21, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 7, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 5, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 31, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Oct 11, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 11, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Dec 19, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 19, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 19, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 16, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 15, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 15, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 6, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 15, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 14, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 14, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 13, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 10, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 6, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| May 6, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 5, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |